Alberto Garaventa

The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report

Susan L. Cohn, Andrew D.J. Pearson, Wendy B. London et al. · Journal of Clinical Oncology · 2008 · 1.8K citations · Full text

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau‐Couanet et al. · The Lancet Oncology · 2018 · 379 citations

Interleukin 2, Autoimmune Disease, Anti-gd2 Antibody Ch14.18/cho +7

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Andrew D.J. Pearson et al. · The Lancet Oncology · 2017 · 334 citations · Full text

Oncology, Medicine, Versus Carboplatin +8

Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma.

Alberto Garaventa, Roberto Luksch, M. S. Lo Piccolo et al. · PubMed · 2003 · 189 citations

European Intergroup Studies (MMT4-89 and MMT4-91) on Childhood Metastatic Rhabdomyosarcoma: Final Results and Analysis of Prognostic Factors

Modesto Carli, Raffaella Colombatti, Odile Oberlin et al. · Journal of Clinical Oncology · 2004 · 178 citations